Tatyana Rudina

Tatyana Rudina

Auto-generated profile, based on publicly available information

Tatyana Rudina

Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
JNJeetendra Kumar Nag
Jeetendra Kumar Nag
HMHodaya Malka
Hodaya Malka
SSshoshana sedley
shoshana sedley
PAPriyanga Appasamy
Priyanga Appasamy
TRTatyana Rudina
Tatyana Rudina
RBRachel Bar-Shavit
Rachel Bar-Shavit
While the role of G-protein–coupled receptors (GPCR) in cancer is acknowledged, their underlying signaling pathways are understudied. Protease-activated receptors (PAR), a subgroup of GPCRs, form a family of four members (PAR1–4) centrally involved in epithelial malignancies. PAR4 emerges as a potent oncogene, capable of inducing tumor generation. Here, we demonstrate identification of a pleckstrin-homology (PH)-binding motif within PAR4, critical for colon cancer growth. In addition to PH–Akt/PKB association, other PH-containing signal proteins such as Gab1 and Sos1 also associate with PAR4. Point mutations are in the C-tail of PAR4 PH-binding domain; F347 L and D349A, but not E346A, abrogate these associations. Pc(4–4), a lead backbone cyclic peptide, was selected out of a mini-library, directed toward PAR2&4 PH-binding motifs. It effectively attenuates PAR2&4–Akt/PKB associations; PAR4 instigated Matrigel invasion and migration in vitro and tumor development in vivo. EGFR/erbB is among the most prominent cancer targets. AYPGKF peptide ligand activation of PAR4 induces EGF receptor (EGFR) Tyr-phosphorylation, effectively inhibited by Pc(4–4). The presence of PAR2 and PAR4 in biopsies of aggressive breast and colon cancer tissue specimens is demonstrated. We propose that Pc(4–4) may serve as a powerful drug not only toward PAR-expressing tumors but also for treating EGFR/erbB-expressing tumors in cases of resistance to traditional therapies. Overall, our studies are expected to allocate new targets for cancer therapy. Pc(4–4) may become a promising candidate for future therapeutic cancer treatment.

3 April 2023
Verified
Other
Open access
JNJeetendra Kumar Nag
Jeetendra Kumar Nag
HMHodaya Malka
Hodaya Malka
SSshoshana sedley
shoshana sedley
PAPriyanga Appasamy
Priyanga Appasamy
TRTatyana Rudina
Tatyana Rudina
RBRachel Bar-Shavit
Rachel Bar-Shavit
Supplementary Data from PH-Binding Motif in PAR4 Oncogene: From Molecular Mechanism to Drug Design

3 April 2023
Verified
Other
Open access
JNJeetendra Kumar Nag
Jeetendra Kumar Nag
HMHodaya Malka
Hodaya Malka
SSshoshana sedley
shoshana sedley
PAPriyanga Appasamy
Priyanga Appasamy
TRTatyana Rudina
Tatyana Rudina
RBRachel Bar-Shavit
Rachel Bar-Shavit
While the role of G-protein–coupled receptors (GPCR) in cancer is acknowledged, their underlying signaling pathways are understudied. Protease-activated receptors (PAR), a subgroup of GPCRs, form a family of four members (PAR1–4) centrally involved in epithelial malignancies. PAR4 emerges as a potent oncogene, capable of inducing tumor generation. Here, we demonstrate identification of a pleckstrin-homology (PH)-binding motif within PAR4, critical for colon cancer growth. In addition to PH–Akt/PKB association, other PH-containing signal proteins such as Gab1 and Sos1 also associate with PAR4. Point mutations are in the C-tail of PAR4 PH-binding domain; F347 L and D349A, but not E346A, abrogate these associations. Pc(4–4), a lead backbone cyclic peptide, was selected out of a mini-library, directed toward PAR2&4 PH-binding motifs. It effectively attenuates PAR2&4–Akt/PKB associations; PAR4 instigated Matrigel invasion and migration in vitro and tumor development in vivo. EGFR/erbB is among the most prominent cancer targets. AYPGKF peptide ligand activation of PAR4 induces EGF receptor (EGFR) Tyr-phosphorylation, effectively inhibited by Pc(4–4). The presence of PAR2 and PAR4 in biopsies of aggressive breast and colon cancer tissue specimens is demonstrated. We propose that Pc(4–4) may serve as a powerful drug not only toward PAR-expressing tumors but also for treating EGFR/erbB-expressing tumors in cases of resistance to traditional therapies. Overall, our studies are expected to allocate new targets for cancer therapy. Pc(4–4) may become a promising candidate for future therapeutic cancer treatment.

3 April 2023
Verified
Other
Open access
JNJeetendra Kumar Nag
Jeetendra Kumar Nag
HMHodaya Malka
Hodaya Malka
SSshoshana sedley
shoshana sedley
PAPriyanga Appasamy
Priyanga Appasamy
TRTatyana Rudina
Tatyana Rudina
RBRachel Bar-Shavit
Rachel Bar-Shavit
Supplementary Figure from PH-Binding Motif in PAR4 Oncogene: From Molecular Mechanism to Drug Design

3 April 2023
Verified
Other
Open access
JNJeetendra Kumar Nag
Jeetendra Kumar Nag
HMHodaya Malka
Hodaya Malka
SSshoshana sedley
shoshana sedley
PAPriyanga Appasamy
Priyanga Appasamy
TRTatyana Rudina
Tatyana Rudina
RBRachel Bar-Shavit
Rachel Bar-Shavit
Supplementary Table from PH-Binding Motif in PAR4 Oncogene: From Molecular Mechanism to Drug Design

3 April 2023
Verified
Other
Open access
JNJeetendra Kumar Nag
Jeetendra Kumar Nag
HMHodaya Malka
Hodaya Malka
SSshoshana sedley
shoshana sedley
PAPriyanga Appasamy
Priyanga Appasamy
TRTatyana Rudina
Tatyana Rudina
RBRachel Bar-Shavit
Rachel Bar-Shavit
Supplementary Figure from PH-Binding Motif in PAR4 Oncogene: From Molecular Mechanism to Drug Design